Postinflammatory hyperpigmentation - I-Postinflammatory Hyperpigmentation
I- I-Postinflammatory Hyperpigmentation (Postinflammatory hyperpigmentation) yisimo sesikhumba esibonakala ngokwanda kombala esikhumbeni kulandela ukuvuvukala kwesikhumba. I- i-postinflammatory hyperpigmentation (postinflammatory hyperpigmentation) ingabangelwa ukuchayeka elangeni isikhathi eside, ukuvuvukala, noma okunye ukulimala kwesikhumba, okuhlanganisa nalokho okuhlobene nezinduna. Abantu abanesikhumba esimnyama ngokuvamile bathambekele kakhulu ekubeni ne-hyperpigmentation kanye nokuchayeka kakhulu elangeni.
☆ Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
References
Postinflammatory hyperpigmentation (PIH) inkinga yesikhumba eyenzeka njalo ngemuva kokuvuvukala kwesikhumba noma ukulimala. Ivamise ukuhlala isikhathi eside futhi iba yimbi kakhulu kubantu abanesikhumba esimnyama (Fitzpatrick skin types III–VI) . Nakuba kuvame ukuba ngcono ngokwakho, lokhu kungathatha isikhashana, ngakho ukwelashwa kuvame ukudingeka isikhathi eside. Ukuhlanganisa izindlela zokwelapha ezihlukene kusebenza kahle kakhulu.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation iyi-sequelae evamile yokuvuvukala kwesikhumba. Kuvamise ukuthinta abantu abanebala elimnyama kakhulu futhi kaningi. Ucwaningo lubonisa ukuthi izinkinga ezifana ne- postinflammatory hyperpigmentation ziphakathi kwezizathu ezinkulu zokuthi kungani abantu abanesikhumba esimnyama bafune ukunakekelwa kwesikhumba. Ukwelashwa kusenesikhathi kubalulekile ekuxazululeni i- postinflammatory hyperpigmentation futhi ngokuvamile kuqala ngokulawula isimo sokuqala sokuvuvukala. Umugqa wokuqala wokwelapha ngokuvamile uhilela ukusebenzisa ama-topical agents akhanyisa isikhumba kanye ne-sunscreen ukuze kuvikelwe. Lawa ma-ejenti, afana ne- hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , anganciphisa ngempumelelo umbala oweqile. Ukwengeza, retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy nazo zisetshenziswa njengama-ejenti okususa umbala, nokwelashwa okusha okuvelayo. Nakuba ukwelapha ngezihloko ngokuvamile kusebenza ngempumelelo ekushintsheni umbala ongaphezulu kwesikhumba, izinqubo (laser, chemical peel) zingadingeka ezimweni ezinenkani. Kubalulekile ukusebenzisa ukuqapha ngalezi zindlela zokwelapha ukuze ugweme ukucasuka kanye nokuba kubi kwe- postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
